Literature DB >> 9621078

Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs.

N Chirmule1, J V Hughes, G P Gao, S E Raper, J M Wilson.   

Abstract

Adenovirus vectors delivered to lung are being considered in the treatment of cystic fibrosis (CF). Vectors from which E1 has been deleted elicit T- and B-cell responses which confound their use in the treatment of chronic diseases such as CF. In this study, we directly compare the biology of an adenovirus vector from which E1 has been deleted to that of one from which E1 and E4 have been deleted, following intratracheal instillation into mouse and nonhuman primate lung. Evaluation of the E1 deletion vector in C57BL/6 mice demonstrated dose-dependent activation of both CD4 T cells (i.e., TH1 and TH2 subsets) and neutralizing antibodies to viral capsid proteins. Deletion of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD8 T cells against target cells expressing viral antigens. Analysis of T-cell subsets from mice exposed to the vector from which E1 and E4 had been deleted demonstrated preservation of TH1 responses with markedly diminished TH2 responses compared to the vector with the deletion of E1. This effect was associated with reduced TH2-dependent immunoglobulin isotypes and markedly diminished neutralizing antibodies. Similar results were obtained in nonhuman primates. These studies indicate that the vector genotype can modify B-cell responses by differential activation of TH1 subsets. Diminished humoral immunity, as was observed with the E1 and E4 deletion vectors in lung, is indeed desired in applications of gene therapy where readministration of the vector is necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621078      PMCID: PMC110420     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

Authors:  D Armentano; J Zabner; C Sacks; C C Sookdeo; M P Smith; J A St George; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 2.  Functional diversity of helper T lymphocytes.

Authors:  A K Abbas; K M Murphy; A Sher
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

3.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; K U Jooss; Q Su; H C Ertl; J M Wilson
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

6.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes.

Authors:  D J Lenschow; K C Herold; L Rhee; B Patel; A Koons; H Y Qin; E Fuchs; B Singh; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

9.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a.

Authors:  J F Engelhardt; L Litzky; J M Wilson
Journal:  Hum Gene Ther       Date:  1994-10       Impact factor: 5.695

View more
  19 in total

Review 1.  An advance in liver-specific gene delivery.

Authors:  D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Hepatitis B virus vector carries a foreign gene into liver cells in vitro.

Authors:  Junhee Yoo; Jinkyung Rho; Dongheon Lee; Suho Shin; Guhung Jung
Journal:  Virus Genes       Date:  2002-06       Impact factor: 2.332

3.  Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions.

Authors:  N Chirmule; S E Raper; L Burkly; D Thomas; J Tazelaar; J V Hughes; J M Wilson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

5.  Development of optimized vectors for gene therapy.

Authors:  G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

Review 6.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

7.  "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung.

Authors:  M A Croyle; N Chirmule; Y Zhang; J M Wilson
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Increased sensitivity to staphylococcal enterotoxin B following adenoviral infection.

Authors:  Timur O Yarovinsky; Michael P Mohning; Mary A Bradford; Martha M Monick; Gary W Hunninghake
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

9.  Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle.

Authors:  N Chirmule; W Xiao; A Truneh; M A Schnell; J V Hughes; P Zoltick; J M Wilson
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung.

Authors:  Y Peng; J Trevejo; J Zhou; M W Marino; R G Crystal; E Falck-Pedersen; K B Elkon
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.